Results 151 to 160 of about 5,941 (192)
Disrupting linearity of PROTAC scaffolds prevents off-target complex I inhibition
Richert N +12 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1998
Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition of the proton pump by rabeprazole is partially reversible. Rabeprazole has 2- to 10-fold greater antisecretory activity than omeprazole in vitro.
A, Prakash, D, Faulds
+5 more sources
Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition of the proton pump by rabeprazole is partially reversible. Rabeprazole has 2- to 10-fold greater antisecretory activity than omeprazole in vitro.
A, Prakash, D, Faulds
+5 more sources
CYP2C19 genotype and the PPIs - focus on rabeprazole
Journal of Gastroenterology and Hepatology (Australia), 2005 Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism.
Wong, BCY, Goh, KL, Lim, PWY
exaly +2 more sources